Clinofibrate
Chemical compound
- none
- In general: ℞ (Prescription only)
- 2-(4-{1-[4-(1-carboxy-1-methylpropoxy)phenyl]cyclohexyl}phenoxy)-2-methylbutanoic acid
- 30299-08-2
Y
- 2787
- DB09006
N
- 21613360 N
- 0374EZJ8CU
- D01300 Y
- ChEMBL1897738 N
- DTXSID6046638
- Interactive image
- CCC(C)(C(=O)O)OC1=CC=C(C=C1)C2(CCCCC2)C3=CC=C(C=C3)OC(C)(CC)C(=O)O
InChI
- InChI=1S/C28H36O6/c1-5-26(3,24(29)30)33-22-15-13-20(14-16-22)28(17-8-7-9-18-28)21-11-10-12-23(19-21)34-27(4,6-2)25(31)32/h10-16,19H,5-9,17-18H2,1-4H3,(H,29,30)(H,31,32)N
- Key:OGGAHXJZRRGBTK-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Clinofibrate (INN) (trade name Lipoclin) is a fibrate and a derivative of Bisphenol Z.[1]
Synthesis
The reaction between cyclohexanone and phenol gives Bisphenol Z (3).[2] This is treated with chloroform and methyl ethyl ketone in the presence of base. The resulting Bargellini reaction gives clinofibrate.[3]
References
- ^ Takeuchi N, Kukita H, Kajiyama G, Fujiyama M, Ishikawa K, Miki H, Mishima T, Murata K, Asano T (April 1982). "Effect of clinofibrate, a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia". Atherosclerosis. 42 (2–3): 129–39. doi:10.1016/0021-9150(82)90145-9. PMID 7073798.
- ^ Patil LS, Suryawanshi VS, Pawar OB, Shinde ND (2011). "An Improved, Highly Efficient Method for the Synthesis of Bisphenols". e-Journal of Chemistry. 8 (4): 2016–2019. doi:10.1155/2011/372673.
- ^ US 3716583, Nakamura Y, Aono S, Agatsuma K, Tanaka Y, "Phenoxy carboxylic acid derivative", issued 13 February 1973, assigned to Sumitomo Chemical Company
- v
- t
- e
| Cholesterol absorption inhibitors, NPC1L1 | |
|---|---|
| Bile acid sequestrants/resins (LDL) |
| Statins (HMG-CoA reductase, LDL) | |
|---|---|
| Niacin and derivatives (HDL and LDL) | |
| MTTP inhibitors (VLDL) | |
| ATP citrate lyase inhibitors (LDL) | |
| Thyromimetics (VLDL) |
| PPAR agonists (LDL) |
| ||||
|---|---|---|---|---|---|
| CETP inhibitors (HDL) | |||||
| PCSK9 inhibitors (LDL) | |||||
| ANGPTL3 inhibitors (LDL/HDL) |
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
